Magnesium Treatment in Hypoparathyroidism

University of Tartu

Status: Completed

Conditions: Hypoparathyroidism

Treatments: Dietary Supplement: magnesium

Study type: Interventional

Funder types: Other

Identifiers

NCT00824226

UT296

Details and patient eligibility

About

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• primary or secondary hypoparathyroidism
• treatment with calcium plus vitamin D analogue
• ionized calcium 1,0-1,29 mmol/L
• magnesium level 0,7-1,05 mmol/L
• TSH 0.1- 10 imU/L

Exclusion criteria

• any other disease known to influence plasma Ca level
• pregnancy
• creatinine > 150 microM/L
• patient has used supplementary magnesium within 2 previous months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)